Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: IMDX

Insight Molecular Diagnostics Inc.

Healthcare | Medical - Diagnostics & Research

No licensed closing price on file for IMDX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.52

Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) is a diagnostics and research company. Figures from SEC EDGAR; updated 2026-10-20 10:22 UTC.

What Insight Molecular Diagnostics Inc. does

iMDx is a diagnostics technology company developing molecular tests to detect organ transplant rejection and support oncology treatment decisions. The company's primary focus is decentralized transplant testing through its GraftAssure product line, which measures a biomarker called donor-derived cell-free DNA using digital PCR instruments made by Bio-Rad Laboratories. The company operates a CLIA-certified laboratory in Franklin, Tennessee that currently offers transplant rejection testing, while developing kitted versions for clinical use that require FDA approval before clinical deployment.

Summarized from Insight Molecular Diagnostics Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.52

Revenue, margins & earnings

FY2021: net loss $64M on revenue $2M$2MFY2021FY2022: net loss $73M on revenue $958,000$958,000FY2022FY2023: net loss $28M on revenue $2M$2MFY2023FY2024: net loss $61M on revenue $2M$2MFY2024FY2025: net loss $50M on revenue $4M$4MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-07-06
Most recent filed transactions — July 2026:
  • 2026-07-06DirectorTax withholding-12,100$68.8K
  • 2026-07-06DirectorTax withholding-7,700$43.8K
  • 2026-07-06DirectorTax withholding-7,700$43.8K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Insight Molecular Diagnostics Inc. do?

iMDx is a diagnostics technology company developing molecular tests to detect organ transplant rejection and support oncology treatment decisions.

When did IMDX last file with the SEC?

Insight Molecular Diagnostics Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-17. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 10:22 UTC. This page is also available as JSON at /api/data?ticker=IMDX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for IMDX and 5,000+ tickers.

Create a free account — keep IMDX
For your agent
GET /api/data?ticker=IMDX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt